This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trilostane for Androgen-Independent Prostate Cancer

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: September 9, 2005
Last updated: December 2, 2013
Last verified: December 2013
The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.

Condition Intervention Phase
Prostate Cancer Prostate Adenocarcinoma Drug: Trilostane Drug: Hydrocortisone Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • activity of trilostane in men with androgen-independent prostate cancer. [ Time Frame: 4 years ]

Secondary Outcome Measures:
  • serum levels of gonadal and adrenal steroids [ Time Frame: 4 years ]

Enrollment: 24
Study Start Date: March 2004
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Trilostane
    Taken orally once a day for three days then twice daily thereafter.
    Drug: Hydrocortisone
    Taken orally with trilostane.
Detailed Description:
  • Patients will take trilostane orally once a day for three days, then twice a day thereafter.
  • Patients will complete a daily drug log recording the date, time and number of capsules taken.
  • Trilostane may moderately decrease the production of steroids by the adrenal glands. In order to prevent any symptoms related to decreased steroid production, patients will also take hydrocortisone at the same time as the trilostane.
  • While the patients are on treatment blood work will be done after 2 weeks and then every 4 weeks to test the levels of PSA in the blood. On weeks 4 and 8 of treatment additional blood work will be done to check hormone levels. Blood pressure and pulse rate will also be taken every 4 weeks.
  • Depending upon disease status, radiological testing (CT scan, x-rays, and/or bone scan) may be repeated every 12 weeks.
  • Patients will remain on study treatment as long as their disease responds and they do not experience any severe side effects.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed prostate adenocarcinoma
  • Disease progression despite androgen depravation therapy and antiandrogen withdrawal
  • Progressive measurable disease or bone scan progression or PSA progression
  • Serum total testosterone < 50ng/ml
  • Creatinine < 2.0 mg/dl
  • ALT < 2 x ULN
  • CALGB performance status of 0,1, or 2

Exclusion Criteria:

  • Radiation therapy within 4 weeks
  • Antiandrogen within 8 weeks
  • Other secondary hormonal therapy or investigational agents within 4 weeks
  • Prior chemotherapy for androgen-independent prostate cancer
  • History of adrenal insufficiency
  • Known brain metastases
  • Severe liver or renal disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00181597

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Identifier: NCT00181597     History of Changes
Other Study ID Numbers: 04-037
Study First Received: September 9, 2005
Last Updated: December 2, 2013

Keywords provided by Sanofi:
Androgen-independent prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Inflammatory Agents
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017